ERBB2 and neoplasm: Further investigations are needed to reveal the contribution of FcγR and FcγR expressing immune cells to the anti-tumour efficacy of anti-neu mAb and whether FcγR expression can be modulated in the tumour microenvironment to augment mAb-mediated36 effector functions for both immunogenic and non-immunogenic tumours.